engleski

Feasibility, uptake and acceptability of the EmERGE mHealth app in individuals living with stable HIV in five European countries

Purpose: To assess the feasibility, usability & acceptability of a co-designed mHealth supported pathway of care for individuals living with stable HIV. Methods: Following a detailed background assessment, a co-design process was facilitated with community and clinicians at five diverse clinical sites across Europe, informing the development of the platform (Figure 1) within a reduced visit pathway of care. Individuals living with stable HIV (based on WHO criteria) are seen annually by their clinician with interim bloods drawn (6 & 18 months) ; results checked, encrypted and pushed securely to their mobile device alongside medication, appointment and other information. Data are reported on uptake, usability (System Usability Scale (SUS)) and experience over the first year. Results: The platform was successfully co-designed, developed and integrated into hospital ICT systems at the five sites ; GDPR compliance was ensured. 2251 participants enrolled in the study: uptake varied by site (10%-37% of respective cohorts). Reasons for non-participation included: clinician engagement (change to practice ; lack of virtual tariff ; perceptions of digitalising clinical work) ; patient choice (change to current pathway ; no smart phone ; confidentiality) ; technical aspects & research questionnaires also contributed. Of the 1439 individuals with 12 month data available to May 2019: 1222/1316(92.7%) were male ; median age 44 (range 20–75) ; 1077/1288(83.6%) MSM ; and 271/1318(20.6%) non-national at site. Viral load was undetectable at 12 months in 1229/1241(99%) ; no SAEs related to the pathway were reported. Usability rating was excellent: median SUS score 85/100 (IQR 70–95) & patient reported experience positive: 82.9% rated their experience as good/excellent ; 94.2% would recommend to a friend. Conclusions: The EmERGE pathway is a feasible and acceptable option in the menu of care for individuals living with stable HIV. Uptake has varied by site and learning gives insights into factors affecting roll out of such options. To date usability and reported experience is very good.reduced visit pathway of care.

EmERGE mHealth app ; HIV ; Europe

nije evidentirano